Financials in USD. Standardized financial statements.
A compact view of how Emergent BioSolutions Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $742.90M | $1.04B | $1.05B | $1.12B | $1.77B | $1.58B | $1.11B | $782.40M | $560.90M | $488.80M |
| Revenue Growth? | -28.8% | -0.5% | -6.1% | -37.0% | +12.4% | +42.6% | +41.4% | +39.5% | +14.8% | 0.0% |
| Cost of Revenue? | $392.30M | $668.20M | $689.30M | $644.50M | $980.40M | $714.20M | $622.90M | $462.00M | $277.30M | $244.00M |
| Gross Profit? | $350.60M | $375.40M | $360.00M | $473.00M | $793.20M | $863.10M | $483.10M | $320.40M | $283.60M | $244.80M |
| Gross Margin? | +47.2% | +36.0% | +34.3% | +42.3% | +44.7% | +54.7% | +43.7% | +41.0% | +50.6% | +50.1% |
| Operating Expenses? | $240.40M | $484.10M | $1.09B | $643.00M | $451.80M | $424.60M | $369.00M | $230.60M | $159.30M | $139.30M |
| Operating Income? | $110.20M | -$108.70M | -$726.40M | -$170.00M | $341.40M | $438.50M | $114.10M | $89.80M | $124.30M | $105.50M |
| EBITDA? | $208.50M | $53.40M | -$47.00M | $15.70M | $504.20M | $609.20M | $258.90M | $155.10M | $174.70M | $132.90M |
| Income Before Tax | $82.80M | -$142.90M | -$731.20M | -$219.00M | $303.20M | $411.90M | $77.40M | $81.50M | $118.60M | $99.20M |
| Income Tax Expense | $30.20M | $47.70M | $29.30M | -$7.40M | $83.70M | $106.10M | $22.90M | $18.80M | $36.00M | $36.70M |
| Net Income? | $52.60M | -$190.60M | -$760.50M | -$211.60M | $219.50M | $305.80M | $54.50M | $62.70M | $82.60M | $51.80M |
| EPS? | $0.98 | $-3.60 | $-14.85 | $-4.22 | $4.10 | $5.79 | $1.06 | $1.25 | $1.98 | $1.29 |
| Diluted EPS? | $0.93 | $-3.60 | $-14.85 | $-4.22 | $4.06 | $5.67 | $1.04 | $1.22 | $1.71 | $1.13 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality